Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.ORCID iD: 0000-0003-3475-3230
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.ORCID iD: 0009-0002-0666-8952
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Umeå University, Faculty of Medicine, Department of Medical Biosciences, Pathology.
Show others and affiliations
2018 (English)In: The Prostate, ISSN 0270-4137, E-ISSN 1097-0045, Vol. 78, no 4, p. 257-265Article in journal (Refereed) Published
Abstract [en]

Background: Microseminoprotein-beta (MSMB) is a major secretory product from prostate epithelial cells. MSMB synthesis is decreased in prostate tumors in relation to tumor grade. MSMB levels are also reduced in the circulation and MSMB is therefore used as a serum biomarker for prostate cancer. We hypothesized that cancers induce a reduction in MSMB synthesis also in the benign parts of the prostate, and that the magnitude of this response is related to tumor aggressiveness. Reduced levels of MSMB in the circulation could therefore be a consequence of reduced MSMB expression not only in tumor tissue but also in the benign prostate tissue.

Methods: MSMB expression was analyzed in prostatectomy specimens from 36 patients using immunohistochemistry and qRT-PCR. MSMB expression in the benign prostate tissue was analyzed in relation to Gleason score, tumor stage, and distance to the tumor. Furthermore, Dunning rat prostate tumors with different aggressiveness were implanted into the prostate of Copenhagen rats to study if this affected the MSMB expression in the tumor-adjacent benign rat prostate tissue.

Results: In prostatectomy specimens, MSMB expression was reduced in prostate tumors but also in the tumor-adjacent benign parts of the prostate. The reduction in tumor MSMB was related to tumor grade and stage, and the reduction in the benign parts of the prostate to tumor grade, stage, and distance to the tumor. Implantation of Dunning cancer cells into the rat prostate resulted in reduced MSMB protein levels in the tumor-adjacent benign prostate tissue. Rapidly growing and metastatic MatLyLu tumors had a more pronounced effect than slow-growing non-metastatic G tumors.

Conclusion: Our data suggest that aggressive prostate tumors suppress MSMB synthesis in the benign prostate and that this could explain why serum levels of MSMB are decreased in prostate cancer patients. This study suggests that markers for aggressive cancer can be found among factors altered in parallel in prostate tumors and in the adjacent benign tissue.

Place, publisher, year, edition, pages
2018. Vol. 78, no 4, p. 257-265
Keywords [en]
beta-inhibin, Dunning rat prostate tumors, PSP94, TINT, tumor-adjacent benign prostate tissue, tumor-instructed normal tissue
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:umu:diva-144815DOI: 10.1002/pros.23466ISI: 000423474900003PubMedID: 29250809Scopus ID: 2-s2.0-85038239779OAI: oai:DiVA.org:umu-144815DiVA, id: diva2:1187605
Available from: 2018-03-05 Created: 2018-03-05 Last updated: 2025-02-18Bibliographically approved
In thesis
1. Tumor instructed normal tissue: studies of potential extratumoral biomarkers and therapeutic targets in prostate cancer
Open this publication in new window or tab >>Tumor instructed normal tissue: studies of potential extratumoral biomarkers and therapeutic targets in prostate cancer
2021 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Prostate cancer is the most common cancer in men in Sweden and but luckily the majority of the patients will carry on their life without any consequences from the disease. Unfortunately, some will develop aggressive tumors and eventually die. However, current prognostic and diagnostic techniques used to distinguish lethal prostate cancer from harmless prostate cancer are insufficient. It is therefore necessary to find novel diagnostic and prognostic markers, so aggressive prostate cancer can be detected and treated as early as possible whilst allowing non-aggressive variants to be safely left without extensive treatment. Interestingly, aggressive tumors have been shown to induce certain adaptive changes in the non-malignant parts of the tumor-bearing prostate – changes probably necessary for subsequent tumor growth and spread. Our research group have termed this response “Tumor Instructed (and thus Indicating) Normal Tissue (TINT)” and proposed this tissue as an alternative source of diagnostic/ prognostic markers.  The aim of this thesis is to analyze factors related to tumor aggressiveness in prostate TINT. Experimental studies and studies on patient material were executed to investigate potential TINT markers at the mRNA and protein level.

In patients we saw that high expression of lysyl oxidase (LOX) in TINT epithelial cells was associated with poor prognosis and served as a prognostic factor. In an animal model, created by injecting tumor cells into rat prostates, expression of LOX was increased in the surrounding non-malignant tissue. If LOX was inhibited while tumors were establishing in the prostate, tumor growth was decreased. In contrast, if LOX was inhibited after tumors were established, tumor growth was increased. Taken together, this suggests that tumors can induce LOX expression in TINT and that the function of LOX is context dependent.

Another gene that was significantly increased in TINT was heme oxygenase-1 (HO-1). TINT in rat prostates injected with aggressive tumor cells was infiltrated by HO-1 expressing macrophages. In patients, HO-1 expressing macrophages was mainly seen in the invasive front of high-grade primary tumors, which also correlated with the presence of bone metastases. HO-1 expressing macrophages was more common in bone metastases than in primary tumors, and had an inverse correlation to AR expression in castration resistant prostate cancer.

Microseminoprotein-β (MSMB) is normally expressed by prostate epithelial cells but is reduced in prostate tumors. Decreased levels of MSMB in serum are currently used as a biomarker for prostate cancer. Both in experimental studies and in patients, we saw that levels of MSMB were also decreased in TINT and related to tumor aggressiveness. This suggests that decreased levels of MSMB in serum could be caused by decreased levels of MSMB in the non-malignant prostate tissue and that TINT-markers possibly could be measured in blood.

In conclusion, findings presented in this thesis show several alterations in TINT associated with tumor aggressiveness which have good potential of being useful as clinical prognostic markers for prostate cancer after further research.

Abstract [sv]

Populärvetenskaplig sammanfattning

Prostatacancer är den vanligaste cancerformen hos män i Sverige. Varje år diagnostiseras cirka 10 000 män, varav en fjärdedel av patienterna dör av sjukdomen. Det är först när modertumören sprider sig utanför prostatan och bildar metastaser – som den blir farlig för patienten. Med dagens diagnostiska och prognostiska metoder är det ibland svårt att, i ett tidigt skede, särskilja aggressiva tumörer från ofarliga tumörer. Detta medför att vissa män inte får tillräcklig behandling, medan andra får behandling i onödan. Det finns därför ett behov av att förbättra de diagnostiska och prognostiska metoderna – och med större säkerhet avgör vilka patienter som har en aggressiv tumör och därmed behöver behandling, och vilka patienter som utan risk kan vänta med behandling och därmed besparas behandlingsrelaterade biverkningar, så som impotens.

För att diagnosticera prostatacancer tas nålbiopsier från prostatan, vilket innebär att en ytterst liten del av prostatan – mindre än 1% – analyseras. De röntgenmetoder som används kan inte alltid visualisera tumören, vilket gör det svårare att ta biopsier direkt från tumören. Det är därför vanligt att många nålbiopsier enbart innehåller tumörfri normal prostatavävnad.

Vi har, i djurmodeller och patientmaterial, undersökt om den normala prostatavävnaden utanför tumören förändras av tumören och om dessa förändringar skiljer sig mellan aggressiva och mindre aggressiva tumörer. Vi har namngett denna typ av vävnad ”Tumor Instructed (Indicating) Normal Tissue (TINT)”, och vår hypotes är att förändringar i TINT kan indikera att det finns en närliggande tumör och även prognostiskt avgöra tumörens aggressivitet.

Syftet med denna avhandling var att analysera nivåerna av Lysyl oxidase (LOX), Heme oxygenase-1 (HO-1) och Microseminoprotein-β(MSMB) i TINT, i patienter och i en djurmodell, och undersöka om nivåerna var associerade till tumörens aggressivitet. Vi undersökte även om LOX påverkade prostatatumörens tillväxt.

Studierna visar att patienter med höga nivåer av LOX i prostatans normala epitelceller hade en högre risk att dö från sjukdomen. LOX skulle därför kunna användas som en prognostisk markör. LOX är ett enzym som sammanbinder olika proteiner i bindväven. I en djurmodell visar vi att tumörer i prostatan resulterade i ökade nivåer av LOX i den närliggande normala vävnaden. Om enzymets funktion blockerades innan tumören hunnit etablera sig, minskade tumörtillväxten. Om LOX istället blockerades efter tumören etablerat sig, ökade tumörtillväxten. Sammantaget visar vi att tumören inducerar LOX i den omgivande normala prostatan (TINT) och att funktionen av LOX, med avseende på tumörtillväxt, beror på i vilket stadie tumören befinner sig.

Vi visar även, i vår djurmodell, att nivåerna av HO-1 ökar i den omkringliggande normala prostatavävnaden, speciellt runt aggressiva tumörer. HO-1 fanns främst i makrofager som infiltrerade TINT. Trots att makrofager är en del av vårt immunförsvar, visar många studier att de är viktiga för tumörens tillväxt. I patienter visar vi att makrofager med HO-1 fanns främst i den normala vävnaden närmast tumören. Höga nivåer var associerat med ökad tumöraggressivitet och om patienten hade skelettmetastaser. Makrofager med HO-1 var mer vanligt i skelettmetastaser än i modertumören. HO-1 aktiveras normalt vid sårläkning och bryter ner Heme i röda blodkroppar till mindre beståndsdelar som senare återanvänds i produktionen av nya röda blodkroppar. Både HO-1 och dessa beståndsdelar har i andra studier visat sig stimulera tumörtillväxt. Patienter med höga nivåer av HO-1 i sina metastaser skulle därför eventuellt dra nytta av att HO-1 blockeras.

Den tredje potentiella TINT-markören som analyserades var MSMB, ett protein som normalt finns i höga nivåer i prostatan. Tidigare studier visar att MSMB är reducerat i prostatatumörer, men vi visar att MSMB även är reducerat i den normala vävnaden nära en tumör. Mängden MSMB var mindre nära tumören än längre bort, och denna gradient var associerad med tumörens aggressivitet. Minskade nivåer av MSMB i blod ingår idag i den nya modellen STHLM3. Vår studie visar att minskade nivåer av MSMB i blod kan vara ett resultat av minskade nivåer, inte bara i tumören, utan även utanför i TINT.

Sammanfattningsvis visar vi att det finns potentiella markörer i den ”normala” prostatavävnaden hos män med prostatacancer. Dessa TINT-markörer skulle exempelvis kunna analyseras i nålbiopsier som innehåller normal vävnad för att detektera och/eller prognostisera prostatacancer. Fler studier behövs för att undersöka om förändringar i TINT är viktiga för tumörens tillväxt och om TINT-markörer kan mätas i blod.

Place, publisher, year, edition, pages
Umeå: Umeå universitet, 2021. p. 85
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2111
Keywords
Prostate cancer, biomarkers, tumor-instructed normal tissue, extra cellular matrix, macrophages, LOX, HO-1, MSMB
National Category
Cancer and Oncology
Research subject
Pathology
Identifiers
urn:nbn:se:umu:diva-179460 (URN)978-91-7855-441-6 (ISBN)978-91-7855-442-3 (ISBN)
Public defence
2021-02-26, Stora hörsalen, Byggnad 5B NUS, Umeå, 09:00 (English)
Opponent
Supervisors
Available from: 2021-02-05 Created: 2021-02-02 Last updated: 2021-02-03Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Halin Bergström, SofiaJäremo, HelenaNilsson, MariaAdamo, Hanibal HaniBergh, Anders

Search in DiVA

By author/editor
Halin Bergström, SofiaJäremo, HelenaNilsson, MariaAdamo, Hanibal HaniBergh, Anders
By organisation
Pathology
In the same journal
The Prostate
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 842 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf